InvestorsObserver gives Amneal Pharmaceuticals Inc (AMRX) an average valuation score of 40 from its analysis. The proprietary scoring system considers the underlying health of a company by analyzing its stock price, earnings, and growth rate. AMRX currently holds a better value than 40% of stocks based on these metrics. Long term investors focused on buying-and-holding should find the valuation ranking system most relevant when making investment decisions.
AMRX has a trailing twelve month Price to Earnings (PE) ratio of 12.7 which places it around the histroical average of roughly 15. AMRX is currently trading at a average value due to investors paying around what the stock is worth in relation to its earnings. AMRX's trailing-12-month earnings per share (EPS) of 0.46 does justify its share price in the market. Trailing PE ratios do not factor in the company's projected growth rate, thus, some firms will have high PE ratios caused by high growth recruiting more investors even if the underlying company has produced low earnings so far.
AMRX has a 12 month forward PE to Growth (PEG) ratio of 0.36. Markets are undervaluing AMRX in relation to its projected growth as its PEG ratio is currently below the fair market value of 1. 0.460000008's PEG comes from its forward price to earnings ratio being divided by its growth rate. PEG ratios are one of the most used valuation metrics due to its incorporation of more company fundamentals metrics and a focus on the firm's future rather than its past.
AMRX's valuation metrics are strong at its current price due to a undervalued PEG ratio despite strong growth. AMRX's PE and PEG are better than the market average resulting in a above average valuation score.